Stock Track | Nurix Therapeutics Plummets 5.13% as Analysts Cut Price Targets Ahead of Earnings

Stock Track

Apr 09, 2025

Shares of Nurix Therapeutics (NRIX) plunged 5.13% in Wednesday's trading session, as multiple analysts lowered their price targets for the biotechnology company ahead of its upcoming first-quarter earnings report.

Several prominent financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price from $28 to $27, while Wells Fargo made a more significant cut, lowering its target from $32 to $25. Stifel also trimmed its target price to $35 from $36, and Oppenheimer decreased its target to $32 from $35, although it maintained an Outperform rating on the stock.

The series of target price reductions comes as Nurix Therapeutics prepares to release its first-quarter financial results. According to FactSet Research Systems, analysts expect the company to report a loss of $0.76 per share for the quarter. The combination of lowered price targets and the anticipation of a quarterly loss appears to have dampened investor sentiment, contributing to the sharp decline in NRIX's stock price during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159792641"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159792641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159792641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-09 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159792641","market":"hk","top_or_hot":-1,"title":"Stock Track | Nurix Therapeutics Plummets 5.13% as Analysts Cut Price Targets Ahead of Earnings","media":"Stock Track","content":"<p>Shares of Nurix Therapeutics (NRIX) plunged 5.13% in Wednesday's trading session, as multiple analysts lowered their price targets for the biotechnology company ahead of its upcoming first-quarter earnings report.</p>\n\n<p>Several prominent financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price from $28 to $27, while Wells Fargo made a more significant cut, lowering its target from $32 to $25. Stifel also trimmed its target price to $35 from $36, and Oppenheimer decreased its target to $32 from $35, although it maintained an Outperform rating on the stock.</p>\n\n<p>The series of target price reductions comes as Nurix Therapeutics prepares to release its first-quarter financial results. According to FactSet Research Systems, analysts expect the company to report a loss of $0.76 per share for the quarter. The combination of lowered price targets and the anticipation of a quarterly loss appears to have dampened investor sentiment, contributing to the sharp decline in NRIX's stock price during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Nurix Therapeutics Plummets 5.13% as Analysts Cut Price Targets Ahead of Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Nurix Therapeutics Plummets 5.13% as Analysts Cut Price Targets Ahead of Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-09 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Nurix Therapeutics (NRIX) plunged 5.13% in Wednesday's trading session, as multiple analysts lowered their price targets for the biotechnology company ahead of its upcoming first-quarter earnings report.</p>\n\n<p>Several prominent financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price from $28 to $27, while Wells Fargo made a more significant cut, lowering its target from $32 to $25. Stifel also trimmed its target price to $35 from $36, and Oppenheimer decreased its target to $32 from $35, although it maintained an Outperform rating on the stock.</p>\n\n<p>The series of target price reductions comes as Nurix Therapeutics prepares to release its first-quarter financial results. According to FactSet Research Systems, analysts expect the company to report a loss of $0.76 per share for the quarter. The combination of lowered price targets and the anticipation of a quarterly loss appears to have dampened investor sentiment, contributing to the sharp decline in NRIX's stock price during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"","article_id":"1159792641","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159792641","pubTimestamp":1744209746,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Nurix Therapeutics  plunged 5.13% in Wednesday's trading session, as multiple analysts lowered their price targets for the biotechnology company ahead of its upcoming first-quarter earnings report.Several prominent financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price from $28 to $27, while Wells Fargo made a more significant cut, lowering its target from $32 to $25. Stifel also trimmed its target price to $35 from $36, and Oppenheimer de","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics"},"translate_title":"分析师在财报公布前下调目标价，Nurix Therapeutics股价暴跌5.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1},"content_text":"Shares of Nurix Therapeutics (NRIX) plunged 5.13% in Wednesday's trading session, as multiple analysts lowered their price targets for the biotechnology company ahead of its upcoming first-quarter earnings report.\nSeveral prominent financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price from $28 to $27, while Wells Fargo made a more significant cut, lowering its target from $32 to $25. Stifel also trimmed its target price to $35 from $36, and Oppenheimer decreased its target to $32 from $35, although it maintained an Outperform rating on the stock.\nThe series of target price reductions comes as Nurix Therapeutics prepares to release its first-quarter financial results. According to FactSet Research Systems, analysts expect the company to report a loss of $0.76 per share for the quarter. The combination of lowered price targets and the anticipation of a quarterly loss appears to have dampened investor sentiment, contributing to the sharp decline in NRIX's stock price during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}